SCHEMBL1423830

SCHEMBL1423830

CN1CCc2c(c(C(F)(F)F)nn2-c2ccc(CN3CCCC3=O)cc2)C1

nearest known ligand 0.85

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 19/20 0.85
CYP2C9 P11712 7/20 0.77
CYP1A2 P05177 5/20 0.77
CYP2C19 P33261 1/20 0.49
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423479 0.92 GRIA2 (1.00) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL3134820 0.87 GRIA2 (1.00) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL4753813 0.86 GRIA2 (0.98) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL3126029 0.85 GRIA2 (0.96) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL4751483 0.85 GRIA2 (0.82) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL8085766 0.83 GRIA2 (0.76) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL1423683 0.82 GRIA2 (1.00) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL1423594 0.82 GRIA2 (0.77) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL1423846 0.81 GRIA2 (0.76) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6
SCHEMBL1423881 0.80 GRIA2 (0.76) GRIA2CYP2C9CYP1A2CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2086643-B1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LTD (GB) 2011-03-23 EP claimed
EP-2086643-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE Glaxo Group Limited (GB) 2009-08-12 EP claimed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 WO claimed
EP-2086643-B1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LTD (GB) 2011-03-23 EP disclosed
EP-2086643-B1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LTD (GB) 2011-03-23 EP disclosed
US-20100137276-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED 2010-06-03 US disclosed
US-20100137276-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED 2010-06-03 US disclosed
US-20100137276-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED 2010-06-03 US disclosed
EP-2086643-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE Glaxo Group Limited (GB) 2009-08-12 EP disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137276-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GRIN1, GRM2, GRIN3A GRIA2 23/4885CYP2C9 2591/4885CYP1A2 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.